Vertex Pharmaceuticals Inc. Stock Rises 5.6%, Outperforms Peers

Dow Jones08-11

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. rose 5.6% to $523.91 on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.1% to 7,753.11 and Dow Jones Industrial Average falling 0.1% to 53,975.98.

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Inc. closed 1.8% below its 52-week high of $533.67, which the company achieved on July 7th.

The stock outperformed some of its peers, as AbbVie Inc. rose 0.8% to $247.97, Krystal Biotech Inc. rose 1.6% to $331.59, and Arcturus Therapeutics Holdings Inc. fell 4.86% to $7.05.

Trading volume totaled 2.7 million, compared to the 50-day average of 1.6 million.

Data source: Dow Jones Market Data, FactSet

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment